Recurrent Clostridioides Difficile Infection
Aug 15, 2025
Triple Threat to Clostridioides difficile Infections: New Antibiotics, Biotherapeutics & Vaccines
Clostridioides difficile infection (CDI) remains a significant public health challenge worldwide, especially in healthcare settings. Despite advancements in diagnosis and treatment, the Clostridioides difficile infection treatment market is characterized by persistent therapeutic limitations, particularly the high ...
Read More...
Nov 01, 2022
Actinium Announces SIERRA Trial Results; Santhera Seeks FDA Review for Vamorolone; Seres Announces BLA Submission for SER-109; BMS Announces Results of COMMANDS Trial; Boehringer’s PDE4B Moves Late-stage Clinical Testing; FDA Rejects Gilead’s Hepcludex; Approval to J&J’s BCMAxCD3 Bispecific Antibody for Multiple Myeloma; Syncona to Acquire AGTC
Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
